title: The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides.
abstract: The protection of stomach and duodenum in conjecture with anti-inflammatory effect was demonstrated for a novel 15 amino acid peptide, coded BPC 157, a fragment of the recently discovered gastric juice peptide BPC. BPC 157 (i.p./i.g.) was investigated in rats in comparison with several reference standards in three experimental ulcer models (48 h-restraint stress, subcutaneous cysteamine, intragastrical 96% ethanol ulcer tests) (pre-/co-/post-treatment). Only BPC 157 regimens were consistently effective in all of the tested models. On the other hand, bromocriptine, amantadine, famotidine, cimetidine and somatostatin were ineffective (restraint stress). A dose-dependent protection (cysteamine) and/or partial positive effect (related to treatment conditions) (ethanol), was obtained with glucagon, NPY and secretin whereas CCK/26-30/was not effective. Based on Monastral blue studies BPC 157 beneficial effect appears to be related to a strong endothelial protection.
authors.affiliation: CDD, Medical and Veterinary Faculty University of Zagreb, Croatia.
authors.forename: P
authors.initials: P
authors.lastname: Sikiric
authors.forename: S
authors.initials: S
authors.lastname: Seiwerth
authors.forename: Z
authors.initials: Z
authors.lastname: Grabarevic
authors.forename: M
authors.initials: M
authors.lastname: Petek
authors.forename: R
authors.initials: R
authors.lastname: Rucman
authors.forename: B
authors.initials: B
authors.lastname: Turkovic
authors.forename: I
authors.initials: I
authors.lastname: Rotkvic
authors.forename: V
authors.initials: V
authors.lastname: Jagic
authors.forename: M
authors.initials: M
authors.lastname: Duvnjak
authors.forename: S
authors.initials: S
authors.lastname: Mise
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D003543:Cysteamine; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000494:pharmacology*; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000209:etiology; D000431:Ethanol; D005260:Female; D005768:Gastrointestinal Hormones / Q000494:pharmacology*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D008297:Male; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000494:pharmacology*; D011506:Proteins / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000209:etiology; D013312:Stress, Physiological / Q000150:complications
chemical_list: D015259:Dopamine Agents; D005768:Gastrointestinal Hormones; D006635:Histamine H2 Antagonists; D010446:Peptide Fragments; D011506:Proteins; D000431:Ethanol; D003543:Cysteamine; C083833:BPC 157